CGT

868개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved868 programs
CGTLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

anti-CD33 CAR NK cells (anti-CD33 CAR NK cells)

Leukemia, Myeloid, Acute · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTLimited DatastaleTmunity Therapeutics, a wholly …Phase 1

huCART-meso cells (huCART-meso cells)

Pancreatic Cancer; Cancer of the Pancreas · Pancreatic Cancer

#PancreaticCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Discontinued
CGTLimited DatastaleXinqiao Hospital of ChongqingPhase 1

in vivo CAR-T drug based on LNP-mRNA (in vivo CAR-T drug based on LNP-mRNA)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 4Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleAutolus LimitedPhase 1

Anti-TRBC1 CAR-T cells (Anti-TRBC1 CAR-T cells)

Refractory/Recurrent Peripheral T-cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTStandard DatabasestaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22-65s cells (CART22-65s cells)

Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 3Status Discontinued
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 3Status Active
CGTLimited DatastaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22CART infusion (CD22CART infusion)

Leukemia; Acute Lymphoblastic Leukemia · CD22

#CD22#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (EB-DT-CAR-NK)

Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma · Advanced Gastric Adenocarcinoma

#AdvancedGastricAdenocarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting

9 / 44 pages

← PreviousNext →